within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H03A_ThyroidPreparations.H03AA51_LevothyroxineSodiumAndIodineCompounds;

model LevothyroxineSodiumAndIodineCompounds
  extends Pharmacolibrary.Drugs.ATC.H.H03AA51;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>H03AA51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Levothyroxine sodium and iodine compounds (ATC code H03AA51) represent a fixed combination therapy used in the treatment of hypothyroidism and goiter. Levothyroxine is a synthetic form of the thyroid hormone thyroxine (T4), while iodine or its compounds provide a necessary substrate for endogenous hormone synthesis. This drug is mainly indicated where treatment with both hormone and iodine supplementation is appropriate, though such combinations are less commonly used today due to a preference for monotherapies. Levothyroxine alone is widely approved for hypothyroidism; the fixed combination is not universally used.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for fixed combinations of levothyroxine sodium and iodine compounds are not specifically reported in published literature. The following parameters are estimated based on pharmacokinetics of levothyroxine monotherapy in adults with hypothyroidism.</p><h4>References</h4><ol><li><p>Huang, F, et al., &amp; Berse, M (2017). No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. <i>Thyroid : official journal of the American Thyroid Association</i> 27(9) 1118–1127. DOI:<a href=&quot;https://doi.org/10.1089/thy.2017.0085&quot;>10.1089/thy.2017.0085</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28741453/&quot;>https://pubmed.ncbi.nlm.nih.gov/28741453</a></p></li><li><p>Glöbel, B, et al., &amp; Andres, C (1984). [Iodine resorption from PVP-iodine preparations after their use in humans]. <i>Deutsche medizinische Wochenschrift (1946)</i> 109(37) 1401–1404. DOI:<a href=&quot;https://doi.org/10.1055/s-2008-1069385&quot;>10.1055/s-2008-1069385</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6479032/&quot;>https://pubmed.ncbi.nlm.nih.gov/6479032</a></p></li><li><p>Thomas, MC, et al., &amp; Russ, GR (2002). Changes in thyroxine requirements in patients with hypothyroidism undergoing renal transplantation. <i>American journal of kidney diseases : the official journal of the National Kidney Foundation</i> 39(2) 354–357. DOI:<a href=&quot;https://doi.org/10.1053/ajkd.2002.30556&quot;>10.1053/ajkd.2002.30556</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11840377/&quot;>https://pubmed.ncbi.nlm.nih.gov/11840377</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LevothyroxineSodiumAndIodineCompounds;
